Series: The Heart Scare That Almost Killed TRT
Subtitle: How a 2010 study, a flawed meta-analysis, and a media panic nearly derailed testosterone therapy for a generation
Post: 1 of 5
Tags: TRT, cardiovascular risk, Basaria 2010, JAMA, NIH, clinical trials, media and medicine
Word Count: ~1,150
In medicine, as in life, a single bad headline can outlast a thousand careful studies. The story of testosterone therapy and cardiovascular risk is one of the starkest examples of how a small, stopped study published in a prestigious journal — reported on breathlessly by a media that had neither the time nor inclination to read the methods section — nearly derailed a treatment used by millions of men.
The year was 2010. The study was published in JAMA. And the headline, simplified to the point of distortion, was: testosterone causes heart attacks.
It did not go well.
The Basaria Study: What It Actually Said
The study in question was led by Dr. Shalender Bhasin and Dr. Shehzad Basaria, published in JAMA in July 2010. It was a randomized, placebo-controlled trial — the gold standard of clinical research — funded by the National Institute on Aging. The trial was called the TOM trial: Testosterone in Older Men with Mobility Limitations.
The population was specific to the point of clinical selectivity: 209 men, average age 74, all with limitations in mobility (defined as difficulty walking or climbing stairs), all with low or low-normal testosterone levels, and — critically — all with a high burden of preexisting cardiovascular disease, hypertension, obesity, or diabetes. This was not a typical TRT patient. This was a population that, in clinical practice, would have warranted the most cautious possible approach to any new medication.
The intervention was testosterone gel, titrated to target testosterone levels in the mid-normal range. The trial was designed to run for six months.
It was stopped after an average of only five months.
The Numbers That Launched a Thousand Headlines
The data monitoring committee halted the trial early after observing a troubling signal: 23 cardiovascular events in the testosterone group versus 5 in the placebo group. These included cardiovascular-related deaths, myocardial infarction, non-fatal arrhythmias, edema, and pulmonary edema.
That number — 23 versus 5 — looked alarming. And to be fair, the investigators reported it responsibly. They noted that the study was small, that it was stopped early (which tends to inflate apparent effect sizes), and that the population was exceptionally high-risk. The JAMA authors explicitly cautioned against overgeneralizing the findings.
The media, however, was under no such obligation.
The Translation Problem
Within 24 hours of the JAMA publication, wire service stories and health desk reporters had simplified the findings into something like: “Study shows testosterone therapy increases heart attack risk.” Some outlets went further, implying that TRT was broadly dangerous for all men.
What those stories omitted:
The sample size. 209 men. The entire trial enrolled fewer people than most suburban high schools have in a single graduating class. At that sample size, 23 cardiovascular events versus 5 represents a statistically significant cluster, but the confidence intervals are wide enough to drive a truck through.
The population. These men were in their mid-70s, had limited mobility, and many had preexisting cardiovascular disease. This is not the median TRT patient, who is more likely in his 40s or 50s, presenting with fatigue and low libido and no prior cardiac events.
The early stopping problem. Trials stopped early for safety reasons routinely show inflated effect sizes. This is a well-documented statistical phenomenon. A trial that would have shown a 1.5x risk if completed to term might show a 3x risk when stopped at the halfway point. The Basaria trial was stopped at roughly five of six months.
The dose and preparation. The trial used a topical testosterone gel titrated aggressively — some men hit testosterone levels that exceeded the upper end of the normal range. Supraphysiologic dosing increases red blood cell mass, hematocrit, and potentially thrombotic risk in ways that physiologic replacement may not.
None of this exculpated testosterone therapy from further scrutiny. The signal was real enough to warrant concern and additional research. But the nuanced version of “this stopped early in an elderly high-risk population and we don’t know if this applies broadly” was not a headline anyone was going to publish.
What Actually Happened to the Field
The consequences were immediate. Physicians across the country began declining to prescribe testosterone therapy for men they would previously have treated without much hesitation. Endocrinologists and urologists started ordering additional cardiac workups before initiating treatment. Some practitioners stopped prescribing entirely.
In the years immediately following 2010, TRT prescriptions continued to grow — driven partly by aggressive direct-to-consumer marketing — but the medical community was increasingly polarized. Defenders of TRT argued that one small stopped study in an elderly high-risk population said nothing definitive about cardiovascular risk in the broader population. Critics argued that the precautionary principle demanded caution until better evidence emerged.
Both positions were reasonable. The problem is that in the absence of definitive evidence, default positions tend to win. And the default position, after a JAMA paper and a hundred alarming headlines, was caution.
Why This Study Still Matters
The Basaria 2010 study mattered not because it answered the question — it emphatically did not — but because it raised the question loudly enough that it could no longer be ignored. The TOM trial forced the cardiology and endocrinology communities to take cardiovascular safety in TRT seriously. It eventually triggered the large-scale, properly powered trials that would actually answer the question.
It also taught an important lesson about how science journalism works (or doesn’t). A 209-person stopped trial in men with limited mobility is a preliminary safety signal, not a verdict. It is the scientific equivalent of a yellow caution flag, not a red stop sign.
The proper response is more research. The actual response was more headlines.
The definitive research would come. It would take thirteen years, 5,246 patients, and a New England Journal of Medicine paper to get there.
But first, things would get worse before they got better. In 2013 and 2014, a flawed meta-analysis and an FDA warning would push the narrative even further into crisis territory — despite the fact that the underlying data was, to put it charitably, not quite right.
Next up: Post 2 — “The Flawed Meta-Analysis and the FDA Warning: How Counting Errors Shaped National Policy on Testosterone.”
